Universal Beteiligungs und Servicegesellschaft mbH Reduces Stock Position in DaVita Inc. $DVA

Universal Beteiligungs und Servicegesellschaft mbH trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 11.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,984 shares of the company’s stock after selling 6,166 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.06% of DaVita worth $6,550,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Doma Perpetual Capital Management LLC raised its stake in DaVita by 172.3% during the 1st quarter. Doma Perpetual Capital Management LLC now owns 288,360 shares of the company’s stock worth $44,110,000 after acquiring an additional 182,476 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of DaVita in the 2nd quarter valued at about $21,554,000. Northern Trust Corp boosted its position in shares of DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after purchasing an additional 149,858 shares during the period. Nuveen LLC purchased a new position in DaVita during the 1st quarter worth approximately $20,218,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in DaVita in the second quarter valued at approximately $15,902,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 4.1%

NYSE DVA opened at $120.13 on Friday. The stock has a market capitalization of $8.48 billion, a price-to-earnings ratio of 12.37, a PEG ratio of 0.91 and a beta of 1.13. The business’s 50 day moving average is $125.98 and its two-hundred day moving average is $134.57. DaVita Inc. has a 12-month low of $113.97 and a 12-month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a return on equity of 815.62% and a net margin of 5.80%.The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DVA shares. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research report on Wednesday. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Zacks Research downgraded shares of DaVita from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 30th. Truist Financial set a $140.00 price objective on DaVita in a research note on Tuesday, October 14th. Finally, Cowen reissued a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Reduce” and an average target price of $148.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.